News: CSL UPDATE 1-CSL's half-year profit beats estimates on robust blood plasma collections, page-42

I'm not seeing what you are seeing at the 90 day interval in the graphs above.

Obviously we will need to wait for all the Phase 3 results to come in but its worth remembering the timeframe for likelihood of second cardiac events.

"The AEGIS-I results support continued planning for Phase 3 to determine whether increasing cholesterol efflux capacity with CSL112 translates into improved cardiovascular outcomes.”In the US alone, approximately 750,000 heart attacks occur every year1. For those patients who survive, the risk is not over. Approximately one in five will experience a recurrent cardiovascular event within one year, most of those events occur very early – approximately half within the first month"

https://www.worldpharmatoday.com/in...-positive-results-from-csl112-phase-2b-trial/